Akorn-Strides, LLC, a joint venture company formed between Akorn, Inc. and Strides Arcolab Ltd has submitted its first Abbreviated New Drug Application (ANDA) with the Office of Generic Drugs for a lyophilized injectable drug. The proposed drug product is an antibiotic injectable used to treat or prevent infections, which currently has annual sales of over $80 million.
Arun Kumar, executive vice chairman and managing director of the company stated, "It is our continued focus to add niche products and create value to the Akorn-Strides JV. We are delighted that this particular product filing with the FDA would further consolidate the overall strategy".